Ariceum Therapeutics Q4 2022 Investor and Scientific Conference Attendance 

BERLIN, 15 September 2022 – Ariceum Therapeutics (Ariceum), a private biotech company developing a radiopharmaceutical product for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, today announces that its senior management team will be attending and hosting meetings at the following investor and scientific conferences in the fourth quarter of 2022 

Terachem 2022: The Fourth International Symposium on Technetium and Other Radiometals in Chemistry and Medicine 
14-17 September 2022, Forum Brixen, Bressanone, Italy 

9th Immunotherapy of Cancer Conference (ITOC) 
22-24 September 2022, Klinikum der Universität München, Munich, Germany 

Optimum 14th Annual Healthcare Investor Conference 
6 October 2022, Wellcome Collection, London, UK 

European Association of Nuclear Medicine (EANM) 35th Annual Congress 
15-19 October 2022, Barcelona International Convention Centre, Barcelona, Spain 

BIO-Europe 2022 
24-26 October 2022, Leipzig Messe, Leipzig, Germany 

4th Targeted Radiopharmaceuticals EU Summit Europe 
6-8 December 2022, Leonard Royal, Amsterdam, Netherlands 

Presentation by: Chief Executive Officer, Manfred Rüdiger, Ariceum Therapeutics
Title: New Life for Satoreotide-The Antagonist Moves
Date & Time: 6 December, 12.00pm CET

European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress 
7-9 December 2022, Palexpo exhibition centre, Geneva, Switzerland 

If you would like to meet with the Ariceum Therapeutics team at any of the above events, please see contact details below. 

For further information, please contact: 

Ariceum Therapeutics
Manfred Rüdiger, CEO
Email: info@ariceum-therapeutics.com

Optimum Strategic Communications
Hollie Vile, Charlotte Hepburne-Scott, Zoe Bolt
Tel: +44 (0) 20 3882 9621
Email: ariceum@optimumcomms.com